SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): ~~April~~ 9,July 23, 2018

DTHERA SCIENCES

(Exact Name of Registrant as Specified in Charter)

Nevada	333-191175	90-0925768
(State or Other Jurisdiction of Incorporation)	Commission File Number	(IRS Employer Identification No.)

7310 Miramar Rd., San Diego, CA	92126
7310 Miramar Rd Suite 350., San Diego, CA	92126
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (858) 215-6360

__________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o [_] Written communications pursuant to Rule 425 under the Securities Act ~~(17 CFR 230.425)~~

o [_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act ~~(17 CFR 240.14a-12)~~

o [_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act ~~(17 CFR 240.14d-2(b))~~

o [_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act ~~(17 CFR 240.13e-4(c))~~

~~Indicate~~[X] byEmerging ~~check mark whether the registrant is an emerging~~ growth company ~~as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).~~

~~Emerging~~[_] If an emerging growth company x, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

IfItem an3.02 ~~emerging~~Unregistered ~~growth~~Sales company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of ~~the~~Equity ~~Exchange Act~~Securities. ¨

~~Item~~Unregistered ~~5.02~~Sales ~~Departure~~ of ~~Directors~~Equity orSecurities ~~Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~

~~Effective April 6, 2018, the Board of Directors of~~ Dthera Sciences, a Nevada corporation (the “Company”), announced ~~voted~~on toJuly ~~increase~~23, ~~the~~2018, ~~size~~that ofit ~~the~~had ~~Board~~closed ~~from~~a ~~three~~private ~~directors~~placement tooffering ~~four~~of ~~directors and~~shares toof ~~appoint~~its ~~Steve~~common R.stock ~~Martin to~~ (the ~~Board to fill the resulting vacancy~~“Offering”). The ~~Mr.~~Company ~~Martin~~had ~~accepted~~commenced the ~~appointment~~Offering ~~and~~in ~~joined~~late ~~the Board of Directors effective April 9, 2018~~2017.

~~Biographical~~As ~~Information~~of the date of the closing of the Offering, the Company had sold a total of approximately 3,925,000 shares of the Company’s common stock in the Offering, and had raised an aggregate of approximately $2,550,000.

~~Steve~~The R.Offering ~~Martin~~was ~~has~~made served as Chief Financial Officer of AmpliPhi Biosciences Corporation since January 2016. Mr. Martin served as Senior Vice President and Chief Financial Officer of Applied Proteomics, Inc., a molecular diagnostics company, from December 2014 to ~~August~~accredited ~~2015.~~investors ~~From June 2011 to December 2014, Mr~~only. ~~Martin~~No ~~served as~~warrants ~~Senior~~or ~~Vice~~other ~~President~~securities ~~and~~were ~~Chief~~offered Financial Officer of Apricus Biosciences, Inc., a publicly traded pharmaceutical company, and served as the Interim Chief Executive Officer of Apricus from November 2012 through March 2013. From 2008 to January 2011, Mr. Martin served as Senior Vice President and Chief Financial Officer of BakBone Software, a publicly traded software company. During his final 10 months with BakBone until the company’s acquisition in January 2011, Mr. Martin also served as BakBone’s Interim Chief Executive Officer. During 2007 and 2008, Mr. Martin served as a senior consultant and Acting Chief Accounting Office of Leap Wireless International which operated Cricket Communications the ~~domestic provider of voice and data communications~~Offering. From 2005 to 2007, Mr. Martin served as Chief Financial Officer of Stratagene Corporation, a publicly traded research products and clinical diagnostics company. Mr. Martin’s previous experience also includes serving as Controller with Gen-Probe Incorporated, a publicly traded molecular diagnostics company, as well as 10 years with Deloitte & Touche LLP, a public accounting firm. Mr. Martin holds a B.S. degree from San Diego State University and is a certified public accountant (inactive).

InThe ~~connection~~above ~~with~~issuances ~~his~~were ~~appointment~~completed toin reliance on exemptions from registration under Section 4(a)(2) of the ~~Board~~Securities Act of ~~Directors, Mr~~1933 (the “Securities Act”). ~~Martin~~These ~~was~~transactions ~~granted~~qualified for ~~options~~exemption tofrom ~~purchase~~registration upbecause (i) the Company did not engage in any general solicitation or advertising to ~~250,000~~market ~~shares~~the securities; of(ii) each purchaser was provided the ~~Company’s~~opportunity ~~common~~to ~~stock.~~ask ~~The~~questions ~~terms~~and ofreceive answers from the ~~options~~Company ~~are~~regarding the asCompany ~~follows:~~and the ~~options~~issuance; ~~vest~~(iii) ~~one-third~~the onsecurities ~~the~~were ~~first~~issued ~~anniversary~~to persons with knowledge and experience in financial and business matters so that he or she is capable of evaluating the ~~date~~merits and risks of ~~grant;~~an ~~one-third~~investment onin the ~~second~~Company; ~~anniversary~~and of(iv) the recipients received ~~date~~“restricted ofsecurities” ~~grant;~~that ~~and~~include ~~one-third~~a restrictive legend on the ~~third~~certificate, ~~anniversary~~which ofrestricts the ~~date~~shares offrom ~~grant;~~being transferred ~~the~~except ~~options~~pursuant ~~have~~to a ~~contractual~~registration ~~life~~statement ofthat ~~eight~~is ~~years from~~effective with the ~~date~~SEC ofor ~~grant;~~pursuant ~~and~~to ~~the~~an ~~exercise~~exemption ~~price~~from ~~is $0~~registration.~~65.~~

~~SIGNATURES~~Item 7.01 Regulation FD Disclosure.

~~Pursuant~~On toJuly ~~the~~23, ~~requirements of the Securities Exchange Act of 1934~~2018, the ~~Registrant~~Company ~~has~~issued ~~duly~~a ~~caused~~press ~~this~~release ~~report~~regarding the toclosing beof ~~signed~~the onprivate ~~its~~offering, ~~behalf~~which byis ~~the~~attached ~~undersigned~~hereto ~~hereunto~~as ~~duly~~Exhibit ~~authorized~~99.1.

~~Dthera~~The press ~~Sciences~~release ~~By:~~included ~~/s/~~as ~~Edward~~Exhibit ~~Cox~~99.1 ~~Name:~~will ~~Edward~~be ~~CoxTitle:~~deemed ~~Chief~~to ~~Executive~~be ~~Officer~~“furnished” rather than “filed,” pursuant to the rules of the Securities and Exchange Commission

~~Date: April~~Item ~~13,~~9.01 ~~2017~~Financial Statements and Exhibits.

2(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated July 23, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Dthera Sciences
Date: July 23, 2018

	By:	/s/ Edward Cox
	Name: Title:	Edward Cox Chief Executive Officer

Filing Compare · DTHERA SCIENCES